NEW YORK (GenomeWeb News) - Ciphergen today said second-quarter losses narrowed despite a 24-percent drop in second-quarter revenue.
 
The narrowed loss together with news that Bio-Rad will acquire its proteomics instrument business caused shares in Ciphergen to climb 11 percent, or $.11, to $1.09 in mid-afternoon trading.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.